CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 258 enrolled
Drug / intervention
Vorapaxar 2.5 mg +1 moredrug
Likely dose
Vorapaxar 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00617123
NCT00617123Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)

Merck Sharp & Dohme LLC·interventional·Posted Feb 15, 2008·Updated Sep 21, 2018

In Brief

A Phase 3 clinical trial evaluating Vorapaxar 2.5 mg and Placebo for Atherosclerosis and 3 related conditions. Completed, enrolled 258 participants.

Detailed Summary

This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
Countries--
CollaboratorsThe TIMI Study Group, Duke Clinical Research Institute

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 15, 2008
Enrollment StartJul 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago

Interventions

Vorapaxar 2.5 mgdrug

Vorapaxar 2.5 mg oral tablet

Placebodrug

matching placebo oral tablet